Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

AACR 2015

18 - 22 Apr 2015

Pennsylvania Convention Center, Philadelphia, United States of America

'Liquid biopsy' may help earlier detection of lung cancer treatment resistance

Dr Jonas Nilsson - Umeå University, Umeå, Sweden

'Liquid biopsy' may help earlier detection of lung cancer treatment resistance ( Dr Jonas Nilsson - Umeå University, Umeå, Sweden )

Comment: Metastatic triple-negative breast cancer responds to immunotherapy

Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA

Comment: Metastatic triple-negative breast cancer responds to immunotherapy ( Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA )

Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancer

Dr Lorraine Chantrill - Garvan Institute of Medical Research, Darlinghurst, Australia

Real-world targeted treatment based on whole genome sequencing difficult in pancreatic cancer ( Dr Lorraine Chantrill - Garvan Institute of Medical Research, Darlinghurst, Australia )

Comment: Research developments stir hopes for melanoma

Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA

Comment: Research developments stir hopes for melanoma ( Dr Louis Weiner - Lombardi Comprehensive Cancer Center, Washington D.C, USA )

Certain classes of genes in patients that could lead to prostate cancer

Dr Erica Golemis - Fox Chase Cancer Center, Philadelphia, USA

Certain classes of genes in patients that could lead to prostate cancer ( Dr Erica Golemis - Fox Chase Cancer Center, Philadelphia, USA )

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

Dr Susan Prockop - Memorial Sloan Kettering Cancer Center, New York, USA

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Susan Prockop - Memorial Sloan Kettering Cancer Center, New York, USA )

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

Pembrolizumab found to be safe with durable responses in advanced non-small cell lung cancer

Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA

Pembrolizumab found to be safe with durable responses in advanced non-small cell lung cancer ( Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA )

PARP inhibitor combo shows early promise for patients with and without BRCA mutations

Dr Timothy Yap - Royal Marsden Hospital, London, UK

PARP inhibitor combo shows early promise for patients with and without BRCA mutations ( Dr Timothy Yap - Royal Marsden Hospital, London, UK )

Phase III trial shows pembrolizumab preferable to ipilimumab in advanced melanoma

Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Phase III trial shows pembrolizumab preferable to ipilimumab in advanced melanoma ( Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

Long-term, regular aspirin use modestly decreased cancer risk

Prof Andrew Chan - Harvard Medical School and Massachusetts General Hospital, Boston USA

Long-term, regular aspirin use modestly decreased cancer risk ( Prof Andrew Chan - Harvard Medical School and Massachusetts General Hospital, Boston USA )

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

US breast cancer cases expected to increase by as much as 50 percent

Dr Phillip Rosenberg - Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA

US breast cancer cases expected to increase by as much as 50 percent ( Dr Phillip Rosenberg - Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA )

Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive breast cancer

Dr Maura Dickler - Memorial Sloan Kettering Cancer Center, New York, USA

Investigational ER degrader safe, with early signs of antitumour activity against advanced ER-positive breast cancer ( Dr Maura Dickler - Memorial Sloan Kettering Cancer Center, New York, USA )

DNA stool test recommended as screening tool for colon cancer

Dr David Ahlquist - Mayo Clinic, Rochester, USA

DNA stool test recommended as screening tool for colon cancer ( Dr David Ahlquist - Mayo Clinic, Rochester, USA )

How is ganetespib regulating the response of tumour cells in lung cancer?

Dr Erica Golemis - Fox Chase Cancer Center, Philadelphia, USA

How is ganetespib regulating the response of tumour cells in lung cancer? ( Dr Erica Golemis - Fox Chase Cancer Center, Philadelphia, USA )

New immunotherapy yields long-lasting responses in some patients with advanced melanoma

Dr Mark Middleton - University of Oxford, Oxford, UK

New immunotherapy yields long-lasting responses in some patients with advanced melanoma ( Dr Mark Middleton - University of Oxford, Oxford, UK )

Extended overnight fasting may lead to reduced breast cancer risk

Dr Catherine Marinac - University of California, San Diego, USA

Extended overnight fasting may lead to reduced breast cancer risk ( Dr Catherine Marinac - University of California, San Diego, USA )

Incidences of liver cancer rising in the USA

Dr Anna Mae Diehl - Duke University Medical Center, Durham, USA

Incidences of liver cancer rising in the USA ( Dr Anna Mae Diehl - Duke University Medical Center, Durham, USA )

Black women found to have denser breast tissue than white women

Dr Anne Marie McCarthy - Massachusetts General Hospital, Boston, USA

Black women found to have denser breast tissue than white women ( Dr Anne Marie McCarthy - Massachusetts General Hospital, Boston, USA )

New data shows that generic drivers are found in benign conditions

Prof Razelle Kurzrock - University of California, San Diego, USA

New data shows that generic drivers are found in benign conditions ( Prof Razelle Kurzrock - University of California, San Diego, USA )

What are the objectives for CART-meso immunotherapy?

Dr Janos Tanyi - University of Pennsylvania, Philadelphia, USA

What are the objectives for CART-meso immunotherapy? ( Dr Janos Tanyi - University of Pennsylvania, Philadelphia, USA )

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA )

How will genomics be applied to patient therapy in future?

Dr Jean Claude Zenklusen - Director, The Cancer Genome Atlas

How will genomics be applied to patient therapy in future? ( Dr Jean Claude Zenklusen - Director, The Cancer Genome Atlas )

Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma

Dr David Bajor - University of Pennsylvania, Philadelphia, USA

Investigational immunotherapy drug combo safe with early signs of effectiveness in advanced melanoma ( Dr David Bajor - University of Pennsylvania, Philadelphia, USA )

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma

Dr Evan Alley - University of Pennsylvania, Philadelphia, USA

Pembrolizumab showed clinical benefit in malignant pleural mesothelioma ( Dr Evan Alley - University of Pennsylvania, Philadelphia, USA )

New approaches in computational pathology for risk assessment in benign breast diseases

Dr Andrew Beck - Beth Israel Deaconess Medical Center, Boston, USA

New approaches in computational pathology for risk assessment in benign breast diseases ( Dr Andrew Beck - Beth Israel Deaconess Medical Center, Boston, USA )

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective

Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA

Chk1 inhibition combined with standard dose gemcitabine may be safe and effective ( Dr Jeffrey Infante - Sarah Cannon Research Institute, Nashville, USA )

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer, effective in some ( Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA )

US breast cancer cases expected to increase by as much as 50 percent by 2030

Dr Phillip Rosenberg - Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA

US breast cancer cases expected to increase by as much as 50 percent by 2030 ( Dr Phillip Rosenberg - Division of Cancer Epidemiology and Genetics, National Cancer Institute, USA )

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma

Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA

Phase II trial of ipilimumab-nivolumab combo shows promise in advanced melanoma ( Dr Stephen Hodi - Dana-Farber Cancer Institute, Boston, USA )

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication

Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA

New T cell–based immunotherapy shows promise for lethal stem cell transplant complication ( Dr Richard O'Reilly - Memorial Sloan Kettering Cancer Center, New York, USA )

Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker

Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA

Pembrolizumab promising for lung cancer, clinical outcomes correlate with biomarker ( Dr Edward Garon - David Geffen School of Medicine at the University of California, Los Angeles, USA )

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial

Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA

Pembrolizumab is better than ipilimumab for advanced melanoma in phase III trial ( Prof Antoni Ribas - UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA )

More from ecancer